During the past decade, CCM Clinical Research Group conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 2 clinical trials were completed, i.e. on average, 18.2% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 2 clinical trials were completed. i.e. 40% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CCM Clinical Research Group" #1 sponsor was "Otsuka Pharmaceutical Development & Commercialization, Inc." with 3 trials, followed by "Boehringer Ingelheim" with 2 trials sponsored, "Suven Life Sciences Limited" with 2 trials sponsored, "Eisai Inc." with 1 trials sponsored and "Pardes Biosciences, Inc." with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CCM Clinical Research Group" #1 collaborator was "Alzheimer's Association" with 1 trials as a collaborator, "Biogen" with 1 trials as a collaborator, "Clinilabs, Inc." with 1 trials as a collaborator and "National Institute on Aging (NIA)" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "CCM Clinical Research Group" are "Schizophrenia" (3 trials), "Alzheimer Disease" (2 trials), "Agitation" (1 trials), "Agitation in Participants With Dementia of the Alzheimer's Type" (1 trials) and "Agitation in Patients With Dementia of the Alzheimer's Type" (1 trials). Many other conditions were trialed in "CCM Clinical Research Group" in a lesser frequency.

Most popular intervention types in "CCM Clinical Research Group" are "Drug" (10 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "15mg T3D-959" (1 trials), "30 mg T3D-959" (1 trials), "45 mg T3D-959" (1 trials) and "AVP-786" (1 trials). Other intervention names were less common.

The vast majority of trials in "CCM Clinical Research Group" are 11 trials for "All" genders.

Currently, there are NaN active trials in "CCM Clinical Research Group". undefined are not yet recruiting, 4 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in CCM Clinical Research Group, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in CCM Clinical Research Group, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".